Anticancer effect of the antirheumatic drug leflunomide on oral squamous cell carcinoma by the inhibition of tumor angiogenesis
LEF is a potent anticancer agent with antiangiogenic effects on OSCC and might be clinically applicable to OSCC by drug repositioning.
Authors
- Kei Tobiume (ORCID: https://orcid.org/0000-0002-1594-3453)
- Eijiro Jimi (ORCID: https://orcid.org/0000-0003-3616-5299)
- Kouji Ohta (ORCID: https://orcid.org/0000-0002-0603-9171)
- Tomonao Aikawa (ORCID: https://orcid.org/0000-0001-6906-6874)
- Shigehiro Ono (ORCID: https://orcid.org/0000-0002-4721-2145)
- Chieko Niwata
- Takako Naruse
- Misaki Akagi
- Nao Yamakado (ORCID: https://orcid.org/0000-0003-3238-6078)
- Jing Gao
- Miyuki Sakuma
- Takayuki Nakagawa (ORCID: https://orcid.org/0000-0002-3508-0712)
Institutions
- Hiroshima University (JP)
- Kyushu University (JP)
Publication Details
- Journal
- Discover Oncology
- Published
- 2025-01-16
- DOI
- https://doi.org/10.1007/s12672-025-01763-5
- Citations
- 3
- Primary Topic
- Head and Neck Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 5.54
Funders
- Japan Society for the Promotion of Science